跳至主要内容
临床试验/EUCTR2008-007763-16-AT
EUCTR2008-007763-16-AT进行中(未招募)1 期

Topical Imiquimod in Treating Patients with Grade 2/3 Cervical Intraepithelial Neoplasia - ITIC (Imiquimod Therapy in Cervical Intraepithelial Neoplasia)-Trial

Medizinische Universität Wien, Univ.Klinik f.Frauenheilkunde,Abt. f.Gynäkologie und Gyn.Onkologie0 个研究点目标入组 60 人开始时间: 2009年1月26日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
Female

入选标准

  • Caucasian women aged 18 years and older with proven HPV-associated CIN 2/3
  • Colposcopy with fully visible transformation zone and lesion
  • Safe Contraception
  • Signed Informed Consent
  • Negative urine pregnancy test
  • Able to communicate well with the investigator, to understand and comply with the requirements of the study
  • Signed the written informed consent
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Women who are pregnant or lactating or become pregnant during the conduct of the study
  • Symptoms of a clinically relevant illness in the 3 weeks before the first study day
  • History of hypersensitivity to the trial drug or to drugs with a similar chemical structure
  • Participance in another clinical trial within 30 days
  • Immunosuppression (medication, illness)
  • HIV- or Hepatitis infection

研究者

发起方
Medizinische Universität Wien, Univ.Klinik f.Frauenheilkunde,Abt. f.Gynäkologie und Gyn.Onkologie

相似试验

Topical Imiquimod in Treating Patients with Grade... | 临床试验